CJC-1295 with DAC has a half-life of about 6 to 8 days, while the no-DAC version lasts only minutes. Compare the two forms and what the difference means.
CJC-1295 with DAC has an elimination half-life of roughly 6 to 8 days in humans, which makes it one of the longest-acting growth hormone-releasing hormone (GHRH) analogs studied to date. The version without DAC clears in about 30 minutes. That gap — days versus minutes — explains almost everything about how the two peptides behave in research.
What CJC-1295 With DAC Actually Is
CJC-1295 is a synthetic 29-amino-acid peptide modeled on GHRH. It was designed to trigger growth hormone release from the pituitary gland, but the original molecule broke down far too quickly to be practical.
The DAC, short for Drug Affinity Complex, is a small maleimide-based tag attached to the peptide. Once injected, that tag forms a covalent bond with serum albumin, the most abundant protein in blood plasma.
CJC-1295 with DAC is not FDA-approved for human use in the United States. It is sold as a research chemical and labeled "not for human consumption."
CJC-1295 With DAC Half-Life: The Numbers
The reported half-life of CJC-1295 with DAC is approximately 6 to 8 days. In the early clinical work behind that figure, plasma peptide levels stayed detectable for about 6 days after a single subcutaneous dose, and IGF-1 remained elevated for up to two weeks.
Half-life is not the same as duration of effect. A compound is generally considered largely cleared after four to five half-lives, so a 6-to-8-day half-life implies a measurable window closer to a month.
People searching for the cjc 1295 with dac half life are usually trying to work out how often a dose would need to be repeated. Under most research protocols built around this form, the interval is measured in weeks rather than hours.
| Form | Approx. half-life | How it stays in circulation | Typical research dosing interval |
|---|---|---|---|
| CJC-1295 with DAC | 6 to 8 days | Binds albumin covalently through the DAC tag | Once per week or less |
| CJC-1295 without DAC (mod GRF 1-29) | About 30 minutes | No albumin binding; degraded quickly | Multiple times per day |
| Native GHRH | About 5 to 10 minutes | Rapid enzymatic breakdown | Continuous infusion in lab use |
Why the DAC Stretches the Half-Life So Far
The DAC works by turning albumin into a carrier protein. Albumin circulates in the body for roughly 19 days on its own, so a peptide attached to it inherits much of that staying power.
The bond also shields the peptide from the enzymes that would normally chop it apart. Instead of a sharp spike followed by rapid clearance, CJC-1295 with DAC produces a low, steady peptide level spread across several days.
Practical Consequences of a Long Half-Life
- Doses are spaced far apart, often once per week or less in research designs.
- Repeated doses can accumulate in the bloodstream when they are stacked too closely.
- Any side effect tied to the peptide may last longer, because clearance is slow.
CJC-1295 With DAC vs. Without DAC
The cjc-1295 no dac half-life is roughly 30 minutes, several hundred times shorter than the DAC version. The no-DAC peptide, often called mod GRF (1-29), lacks the albumin-binding tag entirely.
The half-life of cjc-1295 no dac is short enough that a single dose is largely cleared within a couple of hours. For that reason it is usually paired with a longer-acting compound and injected more frequently in research settings.
Swapping one form for the other without adjusting the schedule is a common error. The two peptides are not interchangeable on a milligram-for-milligram basis, and they do not produce the same hormone pattern.
What the Half-Life Means for Dosing Schedules
The cjc-1295 dac half-life is what makes weekly or even less frequent dosing plausible in research protocols. One dose keeps peptide levels elevated across the better part of a week.
That long window cuts both ways. It reduces injection frequency, but it also means a dosing mistake takes days to correct rather than hours.
Researchers who want a pulsatile hormone rhythm, closer to the body's natural pattern, generally choose the short-acting form instead.
Safety, Sourcing, and Legal Status
Side effects reported in early studies of CJC-1295 with DAC include injection-site irritation, flushing, headache, water retention, and joint stiffness. Long-term safety data in humans are limited, and no regulator has approved the peptide for any medical use.
Research chemicals are also not held to pharmaceutical manufacturing standards, so purity and actual peptide content can vary between vendors. That variability is a safety concern in its own right.
Anyone weighing personal use of any peptide should speak with a healthcare professional first and treat online benefit claims as unproven rather than established.
Frequently Asked Questions
What is the half-life of CJC-1295 with DAC?
CJC-1295 with DAC has a reported half-life of about 6 to 8 days in humans. That long window comes from the DAC tag, which binds the peptide to albumin in the blood and slows its breakdown. The peptide is not FDA-approved for human use in the United States.
Is CJC-1295 with DAC stronger than CJC-1295 without DAC?
It is not stronger so much as longer-lasting. CJC-1295 without DAC has a half-life of roughly 30 minutes, so it clears quickly and produces a brief pulse of growth hormone release. CJC-1295 with DAC stays in circulation for days, creating a sustained rather than pulsatile signal.
How often is CJC-1295 with DAC dosed in research?
Because of the 6-to-8-day half-life, CJC-1295 with DAC is typically given once per week or less in research settings. More frequent dosing can cause the peptide to accumulate in the bloodstream. These schedules describe laboratory research only and are not medical recommendations.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.